Kenneth Brouwer,
Vice President of Technology and ADME-TOX
Dr. Brouwer is Vice President of Technology, ADME-Tox at BioIVT, which provides solutions to address questions that arise during drug discovery and development in the areas of hepatic drug transport, metabolism, drug interactions, transport and metabolism regulation and hepatotoxicity. Dr. Brouwer has an ongoing interest in the metabolic disease state area and in the NAFLD/NASH area in particular, with recent publications detailing the importance of the adaptive response in the liver to increased intracellular concentrations of bile acids, and the utility of in vitro biomarkers to predict in vivo effects.
Prior to this, Dr. Brouwer served as the Chief Scientific Officer at Qualyst Transporter Solutions, and as Executive Director, at PPD Discovery, where he led the scientific and administrative operations within the preclinical groups. Before joining PPD Discovery, he started the Clinical PK group (Glaxo) and later served as Director, Preclinical Development, at GlaxoSmithKline. He was responsible for the DMPK issues leading to candidate selection, review of candidate project plans, and the transition from candidate selection to full development. Dr. Brouwer has lead and directed large international multidisciplinary project teams and presented at FDA panel reviews.
Dr. Brouwer has over 80 publications in peer reviewed journals and is the holder of 3 patents. Dr. Brouwer serves on the Editorial Advisory Board for the Journal of Pharmaceutical Sciences and the Applied In Vitro Toxicology journal and is a reviewer for several additional journals. Dr. Brouwer is an adjunct faculty member in the Division of Molecular Pharmaceutics at the School of Pharmacy, University of North Carolina.
|
|
|
